Zhi-Fuzi,a Cardiotonic Chinese Herb,a New Medical Treatment Choice for Portal Hypertension?

Abstract

Zhi-Fuzi (Radix Aconiti lateralis preparata) is prescribed fairly frequently in Chinese medicine clinical practice for treating the complications of cirrhosis. However, scientific evidence regarding its efficacy and safety has not been available until now; in addition, its treatment efficacy has not yet been evaluated in well-designed clinical trials. Hence, we investigated the hemodynamic effects of Zhi-Fuzi in conscious rats with portal vein ligation (PVL) and the safety in normal rats. Our study included 3 parts: (i) early administration during which the hemodynamic effects of low and high doses of Zhi-Fuzi (0.4 and 0.8 g/kg twice daily) and propranolol (15 and 30 mg/kg twice daily) administered for 14 days after PVL on male Sprague-Dawley rats were evaluated; (ii) late administration during which the other group of PVL rats received 2.4 g/kg of Zhi-Fuzi twice daily from the 15th to 28th postoperative day; hemodynamic effects were measured when the Zhi-Fuzi treatment was finished; and (iii) safety evaluation during which 2 groups of normal rats were administered Zhi-Fuzi (0.4 and 0.8 g/kg twice daily) for 14 days; biochemical and histopathologic studies were completed after hemodynamic measurement. In early administration the portal pressures in rats receiving low and high doses of Zhi-Fuzi, low and high doses of propranolol, and distilled water were 13.81 ± 0.11, 11.59 ± 0.07, 17.09 ± 0.06, 14.52 ± 0.29, and 20.11 ± 0.22 mm Hg, respectively. The high dose of Zhi-Fuzi exerted more portal hypotensive effects than propranolol and simultaneously ameliorated the systemic arterial hypotension in PVL rats. The late administration of Zhi-Fuzi also significantly reduced the elevated portal pressure (14.56 ± 0.19 vs. 19.50 ± 0.31 mm Hg in control, P < 0.05). There were no adverse effects seen in normal rats receiving Zhi-Fuzi. The results suggest that Zhi-Fuzi is a potential drug for the prophylaxis and treatment of portal hypertension.

Get full access to this article

View all access options for this article.

References

Bosch J, Navasa M, García-Pagán JC, DeLacy AM, Rodes J. Portal hypertension. Med Clin North Am 73:931–953, 1989.

D’Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 38:599–612, 2003.

D’Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 11:243–256, 1997.

Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 305:1371–1374; 1981.

Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites and spontaneous bacterial peritonitis. Gastroenterology 120:726–748, 2001.

Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 5:97–101, 1985.

Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 7:648–653, 1987.

D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19:475–505, 1999.

Lebrec D. Prevention of first variceal bleeding: drugs. In: Groszmann RJ, Bosch J, Eds. Portal Hypertension in the 21st Century. Boston: Kluwer Academic Publishers, pp221–226, 2004.

10.

Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353:2254–2261, 2005.

11.

Chen SY, Li F. Formulae that regulate blood. In: A Clinical Guide to Chinese Herbs and Formulae. New York: Churchill Livingstone, pp148–151, 1993.

12.

Xu XC. Prescription for treating blood disorder. In: Pharmacology of Traditional Chinese Medical Formulae. Beijing: Higher Education Press, pp324–326, 1994.

13.

Huang TK. Fuzi. In: A Handbook of the Composition and Pharmacology of Common Chinese Drugs. Beijing: Chinese Medicine Technology Press, pp921–928, 1994.

14.

Chang HM. Zhi-Fuzi and Chuanwu. In: Pharmacology and Applications of Chinese Materia Medica. (Vol I) Philadelphia: World Scientific Publishing Co Pte Ltd, pp668–673, 1986.

15.

Chojkier M, Groszmann RJ. Measurement of portal systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol 240: G371–G375, 1981.

16.

Hillon P, Blanchet L, Lebrec D. Effect of propranolol on hepatic blood flow in normal and portal hypertensive rats. Clin Sci 63:29–32, 1982.

17.

Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 102:931–935, 1992.

18.

Bosch J, Groszmann RJ. Portal Hypertension. Pathophysiology and treatment. Oxford: Blackwell Scientific Publications, pp72–92, 1994.

19.

Chen HC, Hsieh MT, Chang SS, Liu SL. Long-term reno-cardiovascular effects of orally administered aconiti tuber in humans. Am J Chin Med 18:25–33, 1990.

20.

D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19:475–505, 1999.

21.

Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 13:213–219, 1991.

22.

Bosch J, Pizcueta P, Feu F, Fernandez M, García-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 21:1–14, 1992.